Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs Johnson Controls International PLC — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while Johnson Controls International PLC trades at $152.11 (market cap $94.78B). The key difference: Johnson Controls International PLC is far larger — about 24.1× Edgewise Therapeutics Inc. Common Stock's market cap, and Johnson Controls International PLC pays a 1.02% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Johnson Controls International PLC for 66 Days on average.
| EWTX | JCI | |
|---|---|---|
Market Cap | $3.94B | $94.78B |
Volume | 810,104 | 4,103,814 |
Sector | Health | Basic Materials |
52-Week High | $48.35 | $158.76 |
52-Week Low | $14.89 | $108.54 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $3.48B | $103.61B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Johnson Controls International (JCI) trades at $152.44, down 1.91% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $1.42 beating estimates of $1.30, maintaining a three-quarter beat streak. Revenue trends show recovery from $23.0B in 2024 to $23.6B in 2025, with net income margin expanding significantly to 13.94%. Recent news highlights strong Q3 2026 results with 10% organic sales growth and raised full-year guidance.
JCI presents a compelling investment case with analyst consensus strongly bullish (62% buy ratings) and a $172.50 price target offering 13% upside. Key opportunities include strong demand for data-center thermal management systems and expanding profit margins. Risks include elevated valuation multiples (P/E 44.08) and increasing debt-to-asset ratio (26.06% in 2025). The stock's technical position near key support at $153 requires monitoring for sustained bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
